Browsing Tag
brain cancer
7 posts
What REYOBIQ’s Phase 1 data means for the future of CNS-directed radiopharmaceutical platforms
What does REYOBIQ’s Phase 1 data reveal about the future of CNS-targeted radiopharmaceuticals? Explore the broader neuro-oncology implications.
From lab validation to clinical execution: Adaptin Bio advances a novel glioblastoma therapy toward trials
Find out how Adaptin Bio is moving a novel glioblastoma therapy from lab validation into early clinical execution and what this step means for brain cancer research.
Curasight enters clinic with uTREAT for glioblastoma, advancing dual radiopharma strategy
Curasight starts first-in-human trial of uTREAT in glioblastoma, launching its therapeutic radiopharmaceutical program. Read the full strategic analysis.
Glioblastoma trial for MT027 moves forward as T-MAXIMUM debuts allogeneic cell therapy in CNS
T-MAXIMUM wins FDA clearance for MT027 in glioblastoma. Read how its non-viral, off-the-shelf CAR-T may reshape solid tumor cell therapy development.
Hemogenyx Pharmaceuticals innovates brain cancer treatment with CBR delivery
Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical group, has made a significant advancement in medical science by…
Kazia Therapeutics gets fast track status for paxalisib in glioblastoma
Kazia Therapeutics, an Australian oncology company, has secured fast track designation (FTD) from the US Food and Drug…
Kazia Therapeutics gets US RPDD for paxalisib in childhood brain cancer
Kazia Therapeutics, an Australian biotech company, has secured the rare pediatric disease designation (RPDD) for paxalisib (formerly GDC-0084)…